Apogee Therapeutics (APGE)
NASDAQ:APGE
Top Page
Apogee Therapeutics
(NASDAQ:APGE)
Select Model
Select Model
Rating:61Neutral
Price Target:
$83.00
▲(5.69% Upside)
Action:ReiteratedDate:03/26/26
The score is held back mainly by pre-revenue status and escalating losses/cash burn, partially offset by a strong, low-leverage balance sheet and a major liquidity boost from the recent equity raise. Technicals are supportive with the stock trading above key moving averages, and corporate events are favorable due to positive clinical readouts.
Positive Factors
Low leverage / strong capital base
A very low debt load and a materially expanded equity base provide durable financial flexibility for a clinical-stage biotech. This lowers insolvency risk, improves bargaining power for collaborations or licensing, and supports multi-year clinical programs without near-term debt-servicing pressure.
Negative Factors
Pre-revenue status
With no commercial revenues, the company’s long-term viability depends entirely on successful clinical development, regulatory approval, or value-accretive partnerships. This structural absence of product revenue maintains high execution and commercialization risk over the 2–6 month horizon and beyond.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong capital base
A very low debt load and a materially expanded equity base provide durable financial flexibility for a clinical-stage biotech. This lowers insolvency risk, improves bargaining power for collaborations or licensing, and supports multi-year clinical programs without near-term debt-servicing pressure.
Read all positive factors
Apogee Therapeutics (APGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.46B
Dividend YieldN/A
Average Volume (3M)940.93K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth-58.35%
CountryUS
Employees196
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding55,998,604
10 Day Avg. Volume1,199,757
30 Day Avg. Volume940,931
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.18
Forecast
1Y Price Target
$120.18Price Target Upside53.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.69
Revenue Forecast (FY)N/A
Apogee Therapeutics Business Overview & Revenue Model
Company Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indic...
How the Company Makes Money
As a clinical-stage biotechnology company, Apogee Therapeutics does not have publicly established recurring product revenue from commercialized therapies; accordingly, detailed information about ongoing revenue streams from product sales is null. ...
Apogee Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -284.18M | -216.68M | -74.97M | -39.78M |
| Net Income | -255.84M | -182.15M | -83.98M | -39.78M |
Balance Sheet | ||||
| Total Assets | 937.13M | 753.95M | 401.40M | 152.06M |
| Cash, Cash Equivalents and Short-Term Investments | 730.19M | 520.65M | 395.46M | 151.89M |
| Total Debt | 8.85M | 11.83M | 2.03M | 0.00 |
| Total Liabilities | 33.25M | 37.16M | 21.49M | 9.98M |
| Stockholders Equity | 903.88M | 716.79M | 379.91M | 142.07M |
Cash Flow | ||||
| Free Cash Flow | -232.60M | -172.33M | -74.93M | -16.43M |
| Operating Cash Flow | -227.45M | -171.17M | -74.76M | -16.43M |
| Investing Cash Flow | -179.57M | -300.46M | -273.91M | 0.00 |
| Financing Cash Flow | 396.49M | 495.11M | 315.39M | 168.32M |
Apogee Therapeutics Technical Analysis
Positive
78.53
Price Trends
71.34
Positive
70.78
Positive
56.11
Positive
Market Momentum
0.91
Negative
58.85
Neutral
67.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Positive. The current price of 78.53 is above the 20-day moving average (MA) of 71.91, above the 50-day MA of 71.34, and above the 200-day MA of 56.11, indicating a bullish trend. The MACD of 0.91 indicates Negative momentum. The RSI at 58.85 is Neutral, neither overbought nor oversold. The STOCH value of 67.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APGE.
Apogee Therapeutics Risk Analysis
Apogee Therapeutics disclosed 70 risk factors in its most recent earnings report. Apogee Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Apogee Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $2.03B | 5.74 | 11.16% | ― | ― | ― | |
61 Neutral | $5.46B | -17.91 | -36.77% | ― | ― | -58.35% | |
52 Neutral | $1.73B | -3.82 | -31.07% | ― | 36.26% | -158.98% | |
52 Neutral | $2.76B | -26.90 | -11.10% | ― | 5376.27% | 20.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.23B | -43.06 | -209.33% | ― | 343.41% | 11.91% | |
48 Neutral | $1.81B | -8.55 | -71.66% | ― | -9.21% | -8.84% |
* Healthcare Sector Average
APGE
Apogee Therapeutics
78.53
39.28
100.08%
AGIO
Agios Pharma
29.59
-1.25
-4.05%
OCUL
Ocular Therapeutix
8.33
0.58
7.48%
GLPG
Galapagos
30.64
5.14
20.16%
LQDA
Liquidia Technologies
36.61
21.37
140.22%
IDYA
IDEAYA Biosciences
31.39
13.96
80.09%
Apogee Therapeutics Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Apogee Therapeutics Prices Upsized Public Equity Offering
Positive
Mar 25, 2026
On March 24, 2026, Apogee Therapeutics, Inc. entered into an underwriting agreement with a syndicate led by Jefferies, TD Securities, Stifel and Guggenheim Securities to sell 5,000,000 shares of its common stock at a public offering price of $70.0...
Business Operations and StrategyProduct-Related Announcements
Apogee Therapeutics Announces Positive Phase 2 APEX Maintenance Data
Positive
Mar 23, 2026
On March 23, 2026, Apogee Therapeutics reported positive 52-week maintenance data from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, showing durable and deepening clinical responses with 3- and ...
Business Operations and StrategyProduct-Related Announcements
Apogee Therapeutics Reports Positive Phase 1b Asthma Results
Positive
Jan 6, 2026
On January 6, 2026, Apogee Therapeutics reported positive interim results from a Phase 1b trial of its anti-IL-13 antibody zumilokibart (APG777) in 19 adults with mild-to-moderate asthma and Type 2 inflammation, showing a favorable safety profile,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.